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ABSTRACT     
 
Background: Coeliac disease (CD) is a common, genetically transmitted, immune-mediated 
disease characterized by a mucosal lesion in the small intestine. The mucosal lesion is caused 
by dietary gluten-related proteins and leads to heterogenous symptoms and complications.  
Aims: This study was carried out to evaluate the genetic background of CD. In addition, 
genotype-phenotype correlations and different screening methods for CD in families were 
investigated with special interest on initial HLA genotyping.   
Subjects and methods: The study is based on 54 Finnish families with at least two siblings 
with CD (54 probands, 467 first-degree relatives). First-degree relatives were examined with 
duodenal and skin biopsies, serology, nutritional laboratory measures, symptoms, and HLA 
allele genotyping. A genome-wide scan for susceptibility genes for CD was carried out.  
Results: The prevalence of CD was over 20% in our families. In the genome-wide scan two 
chromosomal regions had a significant association with CD (6p and 2q23-32), and one region 
showed suggestive association (10p). In addition, an association of the CTLA-4 gene (located 
on 2q23-32) with CD was found. The linkage peak at 6p was explained with the known 
association of CD with the HLA genes. In genotype-phenotype studies, a significant gene 
dose effect of the HLA DQB1*0201 allele on the severity of CD was found. The HLA 
genotyping of the DQA1*0501, DQB1*0201, and DRB1*04 alleles proved to be useful in 
excluding about 20% of the non-affected first-degree relatives from further CD screenings. 
The relatives carrying any of the forementioned alleles should be further screened for CD 
despite their gastrointestinal symptoms, which were mild or totally lacking in 76% of CD 
patients diagnosed in our study. Endomysial antibody screening alone would have missed 
17% of the relatives having CD. Antigliadin antibodies were more sensitive, but nonspecific 
for the diagnosis of CD. 
Conclusion: The genetic background of CD remains still partly unknown and needs further 
studies. The HLA DQB1*0201 allele contributes to the phenotype of CD. The determination 
of HLA alleles can be used to exclude a part of relatives from further CD screenings. The rest 
of the relatives should be screened for CD independently of their symptoms.  
 
National Library of Medicine Classification: QU 470, QW 573, QZ 50, WD 175, WR 200 
Medical Subject Headings: Adult; Alleles; Antigens, CD; Antigens, Differentiation/genetics; Biopsy; 
Celiac Disease/complications; Celiac Disease/diagnosis; Celiac Disease/epidemiology; Celiac 
Disease/genetics; Dermatitis Herpetiformis; Family; Finland/epidemiology; Genetic Predisposition to 
Disease; Genetic Screening; Genome; Genotype; HLA Antigens; HLA-DQ Antigens/genetics; HLA-
DR Antigens/genetics, Human; Intestine, Small; Linkage (Genetics); Phenotype; Serologic Tests; 
Siblings 
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1. INTRODUCTION 
Coeliac disease (CD) is a common genetically transmitted disease with a prevalence of 1:50-
250 in Finnish and other Western populations (Fasano et al. 2003, Mäki et al. 2003, Dubé et 
al. 2005, Lohi et al. 2007). CD is characterised by a mucosal inflammation and villous 
atrophy in the small intestine, which leads to malabsorption of nutrients and heterogenous 
symptoms from both the gastrointestinal (GI) tract and the extraintestinal area. The 
pathogenesis of CD is partly unclear, although substantial progress in this field has occurred 
during the recent years. The pathogenesis of CD involves interaction between genetic, 
environmental, and immunological factors. Gluten-related proteins are required for the 
development of CD, and a permanent gluten-free diet (GFD) is currently the only treatment 
available for CD. CD is strongly associated with the human leucocyte antigen (HLA) DQ2 
and DQ8 haplotypes, which are observed in over 90% of patients with CD (Louka et al. 
2003). Based on twin and family studies, the HLA genes explain less than 50% of the genetic 
component of CD (Petronzelli et al. 1997, Bevan et al. 1999a). About 5-22% of the first-
degree relatives of CD probands develop the disease during their lifespan, but the mode of 
inhereditance of CD is unclear (Dubé et al. 2005).    
 
In this study, our aim was to collect Finnish families with at least two siblings with CD for a 
genome-wide scan of CD to identify new genes associated with CD. In addition, our aim was 
to investigate correlations between genotype and phenotype in patients with CD. Moreover, 
different strategies for the screening of CD in families were compared, and the role of HLA 
genotyping in the screening was investigated. Identification of the genes for CD help to 
understand the pathogenesis and heterogeneity of CD, and enable the development of new 
treatment strategies and diagnostic procedures for CD.  
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2. REVIEW OF THE LITERATURE 
2.1 Definition of coeliac disease  
CD is defined as a permanent intolerance for certain dietary cereals in genetically predisposed 
individuals, causing a small-bowel mucosal lesion with villous atrophy, crypt hyperplasia, and 
increased level of intraepithelial lymfocytes (IEL). The small-bowel mucosal lesion gradually 
leads to symptoms related to GI tract and malnutrition. In some patients, however, extra-
intestinal symptoms dominate, while in others the disease is clinically silent. Dermatitis 
herpetiformis (DH) is a skin manifestation of CD. The specific protein in cereals, gluten, 
causes CD and DH. Both the GI mucosal lesion and DH recover with GFD.  
 
2.2 History of coeliac disease 
Cultivation developed about 10 000 years ago. In the beginning, the cultivation was based on 
non-gluten containing cereals; rice, sorghum, millet, and maize. Wild wheat and barley were 
cultivated only in a small area in South East Asia, between South Turkey and Iraq (Greco 
1997). These early cereals were different from modern hybrids and contained few gluten 
components. Farming people spread from South East Asia to Europe and reached Northern 
Europe about 5000-6000 years ago. Gradually, cultivation of wheat, barley, rye, and oats 
became common in Europe. Grains were selected based on their bread-making qualities: i.e. 
for their gluten content. Ultimately, gluten constituted about 50% of the protein content of 
cereals (Greco 1997). In the last few hundred years the amount of gluten in the daily diet has 
substantially increased (Greco 1997). However, some individuals have not adapted to the 
changes in diet, probably because of their genetic background and developed CD.   
 
The “classic” clinical picture of CD (severe steatorrhea and failure to thrive) was first 
described by Dr Samuel Gee in 1888. In the beginning of the 1950s, the dietary wheat and 
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related cereals were detected to be triggers of CD by a Dutch paediatrian W.K. Dicke (Dicke 
1950). Soon after that gluten was recognised to be the toxic agent in CD. At the same time 
Paulley reported small-bowel mucosal villous atrophy with chronic inflammation as a 
characteristic finding in CD (Paulley 1954). Development of peroral intestinal biopsy made 
diagnosis of CD possible (Shiner 1957). In the 1960s the genetic nature of CD (MacDonald et 
al. 1965), and the association of CD with DH were proved (Marks et al. 1966). Classic CD 
presents only a minority of all patients, and CD is a much more common disease than 
previously thought (Collin et al. 1997, Mäki et al. 1997). 
 
2.3   Genetics of coeliac disease 
CD develops as a result of an interaction between genetic, environmental, and immunological 
factors. A strong association with the certain HLA-class I and II molecules was found in 
1970´s (Falchuck et al. 1972, Stokes et al. 1972, Keuning et al. 1976, Ek et al 1978). In 1989 
the association of CD with particular HLA-DQ α/β-alleles was reported (Sollid et al. 1989). 
However, based on twin studies, the HLA genes alone do not explain the genetic background 
of CD, indicating that non-HLA genes are also increasing the susceptibility for CD. CD is 
supposed to be a polygenic, multifactorial (complex) disease, having a non-Mendelian mode 
of inheritance. 
 
2.3.1     Strategies for genetic studies  
Genetic association studies 
Case-control approach 
Population-based association studies compare allele or genotype frequencies between 
unrelated patients and independent unaffected controls. In this type of χ²-based gene studies, 
the risk of false positive results is high, because differences in allele or genotype frequencies 
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can be due to a different ethnic background. Therefore, careful matching of the control group 
is important. A common ethnic background of the study groups decreases the genetic 
heterogeneity between the groups. Most HLA-studies for CD in 1970-1990´s have been done 
using this method. 
 
Family-based association studies 
In family-based association studies, the matching problems of case-control studies have been 
avoided by using family-based controls. The most widely used method is the transmission 
disequilibrium test (TDT), which is a χ²-based test for association and linkage comparing the 
transmissions and non-transmissions of the marker allele from parents to affected offspring 
(Spielman et al.1996). 
 
Genetic linkage analyses  
In linkage analysis methods developed for the identification of predisposing genes in complex 
diseases, the degree of allele sharing between affected sib-pairs or all affected relative pairs is 
compared. The observed allele sharing in families is compared with the sharing probability 
assuming no linkage (Shih et al.2001). If the frequency of an allele is more frequent than 
expected by chance in affected siblings or relatives, the susceptibility gene is supposed to be 
situated in that locus. Among most widely used linkage analyses are the maximum likelihood 
score method (MLS) and the non-parametric linkage method (NPL) (Kruglyak L et al. 1995, 
Kruglyak et al. 1996) 
 
Genome-wide random search  
Genome-wide screening aims to indentify chromosomal regions that are linked to the disease 
investigated. By using this method, it is possible to find novel loci associated with the disease 
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of interest and avoid the bias of previous hypotheses of the pathogenesis of the disease. The 
genome is usually first genotyped for 350-450 microsatellites and the most interesting regions 
are studied further with a denser set of markers. After screening, the standard linkage analysis 
in families is performed. The rate of false negative results in this type of genetic method is 
high since the average inter-marker distance is relatively long.  For complex diseases, the 
results of genome-wide screenings have often been contradictory because of confounding 
factors complicating the studies (Risch 2000). Using single-nucleotide polymorphisms in 
genome-wide scans it is possible to identify genes for any complex diseases. So far, this 
method has not been applied in studies of CD. 
 
Candidate gene approach 
The candidate gene approach can be used both in the association and linkage studies. The 
candidate gene selection is based on the knowledge about the pathogenesis of a disease or on 
the results of genome-wide screenings done for the disease. An advantage of this approach is 
the possibility to detect positive or negative associations using markers in the vicinity of the 
gene accounting for a low frequency of recombination. However, the candidate gene approach 
has limitations if the knowledge of the pathogenesis of a disease is unsufficient. 
 
Animal models 
After the predisposing candidate genes have been identified, specific animal models (knock-
out and transgenic animals) can be used to examine the pathophysiology of a disease. In CD 
good animal models have not been published (Louka et al. 2003), but in DH a model exists 
(Marietta et al. 2004). 
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2.3.2  Family and twin studies  
The importance of genetic factors in CD was first proved by MacDonald et al (1965). The 
prevalence of CD among the first-degree relatives varies between 2 to over 20% (with most 
ranging between 10-12%) depending on the population and relatives examined, the methods 
by which the prevalence was estimated, and the diagnostic criteria used (Table 1, Dubé et al. 
2005). From 30 to 50% of the affected first-degree relatives of patients with CD are 
asymptomatic or have only mild symptoms (Ellis 1981).  
 
The high concordance rate (70-90%) between monozygotic twins gives evidence that CD is a 
heritable disorder, but also that environmental factors play a role in the pathogenesis 
(Hervonen et al. 2000, Greco et al. 2002, Nistico et al. 2006). In dizycotic twins the 
concordance rate is only 10-20% (Greco et al. 2002, Nistico et al. 2006), and in siblings who 
possess the CD-associated HLA-alleles about 25-30% (Mearin et al. 1983). The phenotype of 
gluten sensitivity can vary (CD and/or DH) between monozygotic twins (Hervonen et al. 
2000).  
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2.3.3 HLA genes 
The HLA gene complex on the short arm of the chromosome 6 is a cluster of more than 200 
gene loci (Figure 1). Almost half of the genes encoded in the cluster have an effect on the 
immune system (Louka et al. 2003). The role of the HLA molecules, which are coded by the 
HLA class I and II genes, is to bind and present peptide fragments to T cells.  
 
 
 
 
 
 
 
 
 
 
Figure 1.  Overview of the extended HLA complex on the chromosome 6 (modified from 
Louka et al. 2003). 
 
 
The HLA class II molecules (of the DR, DQ, and DP series) are expressed on the surface of 
antigen presenting cells (APCs) where they can bind and subsequently present peptides to 
CD4+ T-cells, whereas the HLA class I molecules (of the A, B, and C series) present peptides 
to CD8+ cytotoxic T cells (Sollid et al. 2005b). The HLA complex is the most polymorphic 
region in the human genome with about 1500 alleles identified (IMGT/HLA at 
http://www.ebi.ac.uk/imgt/hla/). The peptide-binding sites of the polymorphic HLA variants 
exhibit different form and chemistry and, thus, bind and present different sets of peptides 
(Sollid et al. 2005b). Because of a strong linkage disequilibrium (non-random association of 
Chromosome 6
6p21.31
Genes
DP DQ DR
TNF
B C A F HFE
Class II Class III Class I
MICA, MICB
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linked markers) in the HLA complex, the neighbouring alleles have a tendency to be inherited 
as a block, and they occur more often together than expected by chance based on their gene 
frequencies. This makes it difficult to identify genes involved in disease susceptibility. In the 
1990`s the development of the molecular biological techniques, e.g. polymerase chain 
reaction (PCR) –based genotyping methods, has made it possible to investigate the 
association of the HLA region with CD more accurately at the allelic level, instead of 
serological haplotype determination. 
 
2.3.3.1 Genes encoding the HLA DQ2 and DQ8 molecules   
Strong evidence from different populations indicates that genes encoding the HLA-DQ2 and 
the HLA-DQ8 molecules are the most important predisposing genetic factors in CD (Sollid et 
al. 1989, Sollid et al. 1990, Tighe et al. 1992, Congia et al. 1992, Louka et al. 2003, Karell et 
al. 2003). In the European Caucasian populations over 90 % of the CD patients carry the DQ2 
haplotype encoded by the DQA1*0501 or DQA1*0505 alleles (after this called together as 
DQA1*05), and DQB1*0201 or DQB1*0202 alleles (after this called together as DQB1*02). 
Almost all DQ2-negative CD patients carry the DQ8 haplotype, which is encoded by the 
DQA1*03 and DQB1*0302 alleles, and associated with the DRB1*04 allele (the DR4-DQ8 
haplotype) (Spurkland et al. 1992, Polvi et al. 1998a, Karell et al. 2003). Because of the 
linkage disequilibrium in the HLA region, it has been questioned whether the association of 
the DQ2 and/or DQ8 haplotype with CD is a true association or only a marker for an 
association in the HLA region. However, in functional studies gluten has been shown to 
activate DQ2 and DQ8 restricted T-cells in the small intestine of patients with CD (Lundin et 
al. 1993, Lundin et al. 1994) and the dose of DQ2 alleles has been shown to contribute to the 
number of T-cells activated (Vader et al. 2003).  
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Alleles Haplotypes
DQB1 DQA1 DRB1
0201 0501 0301
X X X
0301 0505 11/12
0202 0201 07
0302 03 04
X X X
DR3-DQ2
DRX-DQX
DR5-DQ7
DR7-DQ2
DR4-DQ8
DRX-DQX
The DQA1*05 and DQB1*02 alleles are located on the same chromosome chain in cis 
configuration or in different chromosome chains in trans configuration (Figure 2) (Sollid et 
al. 2005b). When located in the cis (most usual case) position, the alleles encoding the DQ2 
molecule are the DQA1*0501 and the DQB1*0201 alleles, and when located in the trans 
position, the alleles are DQA1*0505 and DQB1*0202. The DQα chains encoded by the 
DQA1*0501 and the DQA1*0505 alleles differ only by one residue in the leader peptide, and 
the DQβ chains encoded by the DQB1*0201 and the DQB1*0202 alleles differ by one residue 
in the membrane proximal domain. It is unlikely that these differences have any functional 
consequence (Sollid et al. 2005b). Instead, the number of the predisposing alleles, especially 
that of the DQB1*0201 allele, contributes to disease susceptibility (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HLA gene association with CD (modified from Sollid et al. 2005b). Risk alleles for 
CD are marked with grey colour. 
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Although the HLA risk alleles are important, they are not sufficient for the development of 
CD. In Western countries 20-30% of the population carries the DQ2 alleles associated with 
CD, and only a minority (~5%) of them develops CD (Liu et al. 2002, Sollid et al. 2005b). 
Furthermore, only about 25-30 % of siblings of a CD patient who carry the HLA risk alleles, 
will develop CD (Mearin et al. 1983). The HLA-associated risk has been estimated to account 
for 36-40% of the genetic component of CD (Petronzelli et al. 1997, Bevan et al. 1999a). By 
repeating the analysis made by Petronzelli et al. (1997), using a population prevalence of 
1:100 instead of 3:1000, the estimate of the HLA effect on the risk of CD is 53% (Sollid et al. 
2005b).  
 
2.3.3.2 Gene dose effect of the DQ2 haplotype and the DQB1*0201 allele in the HLA 
region 
In several studies the risk of CD has been found to be higher in subjects homozygous for the 
DQ2 haplotype or the DQB1*0201 allele (Table 2). Conflicting data have been published on 
the gene dose effect of the number of the DQ2 haplotype or DQB1*0201 alleles on the age at 
diagnosis and symptoms of CD. Some studies have suggested a gene dose effect of the DQ2 
haplotype on the age at diagnosis (Ploski et al. 1993, Congia et al. 1994, Zubillaga et al. 
2002), whereas other studies have failed to demonstrate such an effect (Polvi et al. 1996, 
Ploski et al. 1996, Greco et al. 1998b, Mustalahti et al. 2002). Similarly, the results of the 
gene dose effect of the DQ2 haplotype or the DQB1*0201 allele on symptoms of CD have 
been controversial (Congia et al. 1994, Polvi et al. 1996, Ploski et al. 1996, Greco et al. 
1998b, Zubillaga et al. 2002).  Zubillaga et al (2002) did not find an association between the 
gene dose effect of either the DQ2 haplotype or the DQB1*0201 allele and the grading of 
villous atrophy in a paediatric study population. Recently, the HLA DQ2 homozygosity has 
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been associated with refractory CD (type II with aberrant T-cells) and enteropathy-associated 
T-cell lymphoma (EATL) (Al-Toma et al. 2006). 
 
Functional studies have given further evidence for the importance of the gene dose effect of 
the DQ2 alleles. Vader et al. (2003) have shown that gluten presented by the HLA-DQ2 
homozygous APCs results in at least 4-fold higher T-cell response compared with gluten 
presentation by the HLA-DQ2 heterozygous APCs. The 3-dimensional structure analyses of 
the HLA II molecules indicate that even small differences between the coding alleles can 
change the peptide binding properties of the HLA molecule (Partanen 1997). Furthermore, as 
the HLA-DQ2 heterozygotes express two distinct DQα and DQβ chains, they can form four 
distinct HLA-DQ-dimers of which only one will be HLA-DQ2. In contrast, all the HLA-DQ 
dimers in HLA-DQ2 homozygotes will be of the HLA-DQ2 type, which is needed in the 
pathogenesis of CD (Koning et al. 2005). In addition, Holm et al. (1992) found a dose 
response effect of the DQA and DQB genes on the number of intraepithelial γδ T cells in CD 
patients and their relatives.  
 
2.3.3.3  Patients with coeliac disease expressing neither the HLA DQ2 nor the HLA DQ8 
 molecules 
The number of CD patients who are not carriers of either the HLA DQ2 (encoded by the 
DQA1*05 and DQB1*02 alleles) or the HLA DQ8 (encoded by the DQA1*03 and 
DQB1*0302 alleles) is low. In the European Genetics Cluster on Celiac disease –study, 61 out 
of 1008 (6.1%) European coeliac subjects carried neither the DQ2 nor the DQ8 haplotypes 
(Karell et al. 2003). However, 57 of 61 subjects carried either the DQB1*02 allele or the 
DQA1*05 allele alone. Thus, only 0.4% carried none of the HLA alleles associated with CD. 
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In another study of Finnish and Spanish patients with CD, 0.7% of patients did not carry any 
of the HLA risk alleles (Polvi et al. 1998a).   
 
2.3.4      Other genes  
The family and twin studies of CD, carried out before 1990´s, suggested that there is at least 
one non-HLA locus for CD. The importance of the non-HLA linked genes has been estimated 
to be greater than that of the HLA genes (Risch et al. 1987, Petronzelli et al. 1997, Bevan et 
al. 1999a). 
  
2.3.4.1     Genome-wide scans 
To determine the localisation of the genes susceptible for CD, several genome-wide scans 
have been undertaken during the last decade (Table 3). So far, the only locus constantly 
replicated is the HLA region, and the chromosomal regions showing evidence for linkage 
have differed among the studies. Altogether, these studies have identified 20-30 chromosomal 
regions that could contain susceptibility gene(s). Several regions are believed to be false 
positives, and some true regions are likely to have been overlooked. Limited sample size and 
heterogeneity between the populations weaken the probability to find the predisposing genes. 
 
The region, which has been most consistently (but not significantly) linked to CD, lies on 
chromosome 5 (5q31-33) (Greco et al. 1998a, Naluai et al. 2001, Liu et al. 2002, van Belzen 
et al. 2003). The 5q region harbours a cytokine gene cluster, which is involved in the T-helper 
cell subset 2 type of immune response. In a meta-analysis of genome-wide scans from several 
European populations, this region was significantly associated with CD (Babron et al. 2003). 
To date, four regions have been indentified as susceptibility loci, ie, CELIAC1 (HLA-DQ), 
CELIAC2 (5q31-33), CELIAC3 (2q33), and CELIAC4 (19p13.11) (Sollid et al. 2005b). Only 
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one non-HLA region, CELIAC3, involves a gene which is likely to be associated with CD 
(cytotoxic T lymphocyte associated gene -4 (CTLA-4)) (Table 4). Recently, the myosin IXB 
gene (MYO9B) was identified as the likely susceptibility gene in the CELIAC4-region in a 
Dutch population (Monsuur et al. 2005), but this finding has not been replicated in other 
studies from different populations (Amundsen et al. 2006, Giordano et al. 2006, Hunt et al. 
2006, Nunez et al 2006b, Cirillo et al. 2007, Latiano et al. 2007, van Heel et al. 2007). In 
addition, a significant association with a gene region 4q23 harbouring the IL2 and IL21 genes  
was found in a recent genomewide association study (van Heel et al. 2007).
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Table 4. Studies on the association of the CTLA-4 gene (and/or CD28 or ICOS genes) with CD. 
 
 
Abbreviations: Fam = families, Contr= controls, “+” = positive association, “-” = no association 
 
First 
author 
Nationality Year Gene N Method Association
Djilali-
Saiah 
French 1998 CTLA-4 101 CD 
130 contr 
case-control + 
Holopainen Finnish 1999 CD28 
CTLA-4 
250 CD family + 
suggestive 
Clot Italian and 
Tunisian 
1999 CTLA-4 272 CD 
232 fam 
family - 
Naluai Swedish and 
Norwegian 
2000 CTLA-4 107 fam family + 
Neuhausen American 2001 CTLA-4 175 CD 
62 fam 
family - 
Popat Swedish 2002d CTLA-4  62 CD  + 
Popat Swedish 2002b CD28 52 CD  - 
Popat Northern European 2002c CTLA-4, 
CD28 
311 CD 
116 fam  
family +  
suggestive 
King British 2002 CTLA-4 166 fam family +  
Mora Italian 2003 CTLA-4 199 CD,  
144 contr 
113 fam  
family 
case-control 
+ 
 
Martin-
Pagola 
Spanish 2003 CTLA-4 43 CD  
41 fam 
family - 
King British 2003 CTLA-4  149 fam family 
 
- 
Van 
Belzen 
Dutch 2004a CTLA4  215 CD  
215 contr 
case-control + 
borderline 
Amundsen Swedish and 
Norwegian 
2004 CD28 
CTLA-4 
ICOS 
325 fam family + 
Haimila Finnish 2004 CTLA-4 
CD28 
ICOS 
106 fam family -  
Holopainen European 2004 CTLA-4 
CD28 
ICOS 
796 fam family + 
Hunt British 2005 CTLA-4 
ICOS 
340 CD 
973 contr 
case-control + 
Brophy Irish 2006 CTLA-4 
CD28 
ICOS 
394 CD, 
421 contr 
case-control + 
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2.3.4.2   Candidate gene regions 
The non-HLA candidate gene regions which were identified in the first genome-wide scan 
(Zhong et al. 1996) have been further examined in linkage studies of CD families. Houlston et 
al. (1997) found a weak evidence for 15q26, whereas other investigators failed to find 
evidence for an association (Brett et al. 1998, Neuhausen et al. 2001, Susi et al. 2001). In the 
second genome-wide scan, some evidence for an association with the region 5q was reported 
(Greco et al. 1998a), but in a further study with a new sample of 89 Italian sibpairs, the 
linkage was not any more suggestive to the 5q region (Greco et al. 2001). However, when the 
the original and new sib pair sets were combinied, the linkage to region 5q reached suggestive 
evidence for an association (MLS 2.92). The same group replicated their findings using a 
denser marker set in the region 5q (MLS 2.53) (Percopo et al. 2003). In a Finnish study 
including 102 families, an association with the region 5q was found only for a small subgroup 
of families having both CD and DH (Holopainen et al. 2001). King et al. (2001) 
reinvestigated 17 potential gene regions, which they identified in their original whole genome 
scan, in a larger set of pedigrees, and found a suggestive linkage to the 11p11 region.  
          
2.3.4.3   Candidate genes 
Potential candidate genes include genes regulating the immune function and the other stages 
of CD pathogenesis. Of candidate genes for CD investigated during the recent years (Table 5) 
only the locus on chromosome 2q33 containing the CTLA-4, CD28, and ICOS genes has 
given constant association (Table 4). CD28 and CTLA-4 molecules are expressed by T 
lymphocytes and interact with their ligands B7-1 (CD80) and B7-2 (CD86) during antigenic 
stimulation of T cells via the T cell receptor. CD 28 provides a co-stimulatory signal to T cell 
activation, while CTLA-4 provides a negative signal and thus is thought to be an important 
regulator of autoimmunity (King et al. 2002).  
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2.3.5    Genetics of dermatitis herpetiformis  
DH is associated with the same HLA alleles as CD (Hall et al. 1991, Balas et al. 1997, 
Spurkland et al. 1997, Karell et al. 2002). CD and DH have been found to cluster in the same 
families (Marks et al. 1970, Reunala et al. 1976, Hervonen et al. 2002). Differences in the 
genetic background of CD and DH might explain the phenotype differences between them but 
thus far, no other genes, except for the HLA alleles, have been found to be associated with 
DH. 
 
2.4    Pathogenesis of coeliac disease 
The pathogenesis of CD involves interaction between environmental, genetic, and 
immunological factors.  
 
2.4.1 Environmental factors 
2.4.1.1   Gluten and related proteins 
Proteins in wheat, rye, and barley are environmental factors that are required for the 
development of CD. CD-activating proteins are collectively termed “gluten”, but, actually, 
gluten is the name for the CD-activating proteins (gliadin and glutenin subcomponents) in 
wheat. The closely related proteins in barley and rye are termed hordeins and secalins, 
respectively. Wheat, rye, and barley have a common ancestral origin, whereas oats is not so 
closely related to them (Kagnoff 2005). The proteins of oats, avenins, have a lower content of 
glutamines and prolines, and, rarely, if at all, activate CD (Janatuinen et al. 1995, Reunala et 
al. 1998, Janatuinen et al. 2002). Rice, maize, sorghum, and millet are still more distantly 
related and do not cause CD. 
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Gluten contains two major protein fractions, gliadins and glutenins. Toxic sequences are 
identified in both protein components of gluten as well as in similar proteins in rye and 
barley. High glutamine and proline contents of the gliadins, glutenins, hordeins and secalins 
play a key role in the pathogenesis of CD. Many gliadin peptides have shown to possess 
bulky hydrophobic amino acids followed by proline, which block the activity of intestinal 
peptidases (Arenz-Hansen et al. 2002). Shan et al. (2002) have recently identified a 33-amino-
acid (33-mer) peptide, which is very resistant to digestion by gastric, pancreatic, and intestinal 
brush-border membrane proteases in vitro and in vivo. Furthermore, that peptide has a high 
affinity for tissue transglutaminase (tTG) enzyme, which has a central role in the pathogenesis 
of CD. After deamidation by tTG, the 33-mer peptide enters the APC. In the APC the peptide 
is processed to three epitopes, which bind to the HLA-DQ2 or HLA-DQ8 molecules and 
which have been previously shown to initiate an adaptive immune reaction with T-cell 
response in the small intestine of a CD patient (Lundin et. al 1993, Lundin et. al 1994). 
Homologs of this peptide have been found in all grains that are toxic to CD patients but were 
absent from non-toxic food grains, also from oats (Shan et al. 2002). Recent reports have 
suggested that certain gluten peptides, e.g. α-gliadin p31-43 or p31-49, might have direct 
toxic effects via innate immune system on the pathogenesis of CD, distinct from those 
recognised by T-cells on the intestinal epithelium (Maiuri et al. 2003, Hüe et al. 2004). 
 
The highest allowable daily intake of gluten by CD patients is a matter of debate. A daily 
consumption of < 50 mg, compared with an average of about 13 g in most Western countries, 
is considered safe by many experts (Schuppan et al. 2000, Collin et al. 2004, Hischenhuber et 
al. 2006). However, gluten sensitivity differs among individuals (Collin et al. 2004).  
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2.4.1.2   Other environmental factors 
Apart from gluten, the interaction of environmental factors in CD is poorly understood. Breast 
feeding and the age when gluten is added to diet (Ivarsson et al. 2002), viral infections 
(Kagnoff et al. 1987, Monteleone et al. 2001, Stene et al. 2006, Zanoni et al. 2006), and 
smoking are some of the factors that might contribute to the development of CD (Vasquez et 
al. 2001).  
 
2.4.2    Tissue tranglutaminase enzyme 
In 1997 the tTG enzyme was identified to be the target of endomysial antibodies (EMA), the 
presence of which is an indicator of CD (Dieterich et al. 1997, Dieterich et. al 1998). The tTG 
enzyme is an intracellular enzyme, found for example in fibroblasts, erythroblasts, 
mononuclear, and epithelial cells. During wounding, tTG is released to the extracellular 
space. The tTG is a multifunctional enzyme taking part in for example angiogenesis and 
wound healing. The tTG is also expressed on the subepithelial layer of intestinal epithelium, 
where tTG deamidates the glutamine residues in gliadin, resulting in negatively charged 
glutamic acids (Molberg et al. 1998). These deamidated peptides adhere strongly to the 
binding grooves of the HLA-DQ2 and DQ8 molecules, which present them to CD4+ 
lymphocytes and elicit strong T-cell responses (Molberg et al. 1998, van de Wal et al. 1998). 
Further studies revealed that tTG acts on only selected glutamines and that some gluten 
peptides became better binders to the DQ2 or DQ8 molecules after the deamination (Shan et 
al. 2002, Vader et al. 2002).  
 
2.4.3   Immunological factors and the role of the HLA II genes 
In some genetically susceptible individuals, ingestion of gluten or closely related proteins 
leads to infiltration of the intestinal mucosa by CD4+ lamina propria lymphocytes (the 
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activation of adaptive T-cell mediated immune response). In addition, the innate immune 
system is activated. These immune reactions together lead to crypt hyperplasia and villous 
atrophy (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pathogenesis of CD (modified from van Heel et al. 2006) is divided in three 
major series of events: luminal and early mucosal events, activation of pathogenic CD4+ T-
cells, and subsequent events leading to tissue damage (Kagnoff 2005). Gluten is partially 
digested in intestinal lumen but the key toxic sequences are resistant to intestinal peptidases. 
In lamina propria, tTG deamidates the proline-rich peptides. APCs present these peptides to 
the DQ2 or DQ8 restricted populations of CD4+ T cells, which become activated and release 
cytokines that ultimately lead to tissue damage. Some gluten peptides, e.g p31-43/49 may 
directly induce IL-15 production from enterocytes and APCs. The increase in IL-15 levels 
leads to NKG2D and MICA upregulation on IELs and enterocytes, respectively, and results in 
enterocyte destruction. In addition, B-cell activation and humoral response are involved in the 
pathogenesis of CD. 
 
 
CD4+ T-cells in the lamina propria recognise predominantly deamidated gluten peptides, 
which are presented to them by the genetically determined HLA-DQ2 or HLA-DQ8 
Wheat
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molecules on the cell surface of APCs (Molberg et al. 1998). The x-ray crystal structure of 
DQ2 complexed with gliadin peptides provides an atomic explanation why DQ2 is capable of 
binding certain gluten peptides with high affinity (Kim et al. 2004). The peptide complexes 
are shown to activate DQ2 or DQ8 restricted T-cells, which can be isolated from the small 
intestine of patients with CD (Lundin et al. 1993, Lundin et al. 1994, Shan et al. 2002). 
Gluten-reactive CD4+ T cells produce cytokines and are likely to control the inflammatory 
reactions that produce the CD lesion (Sollid et al. 2005a). When activated, gluten-reactive 
CD4+ cells produce mainly Th1 type cytokines, most notably γ-interferon (IFN-γ) (Nilsen et 
al. 1995).  
 
Recent studies suggest a role for innate immune system in the pathogenesis of CD. It is not 
clear which part of gluten stimulates the innate immune system, although a peptide 31-43 of a 
particular α-gliadin has shown to induce a rapid activation of factors in the innate immune 
system in biopsies of treated CD patients and increase the expression of interleukin (IL)-15 
(Maiuri et al. 2003, Di Sabatino et. al 2006). IL-15 stimulates T cells to migrate to the 
epithelium and facilitate killing of enterocytes by upregulated expression of MIC by 
enterocytes and NKG2D by IELs (Maiuri et al. 2000, Maiuri et al. 2001, Mention et al. 2003, 
Hüe et al. 2004). IELs are likely to be a key factor in the development of refractory CD and 
EATL (Cellier et al. 1998, Cellier et al. 2000). Involvement of infectious agents and innate 
immunity via activation of B-cells and humoral response has also been suggested to be 
involved in the pathogenesis of CD (Halttunen et al. 1999, Zanoni et al. 2006, Barone et al. 
2007). Gluten also induces production of the intestinal peptide zonulin, which acts on 
junctions in mucosal epithelium and increases epithelial permeability (Clemente et al. 2003).
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2.5   Clinical aspects of coeliac disease 
2.5.1   Clinical features of coeliac disease 
CD was originally thought to be a rare disease occuring mainly in childhood and expressing 
with overt symptoms related to GI tract and malnutrition (the classic CD). Later on it was 
understood that CD is underdiagnosed, can develop at any age, and has highly variable 
clinical manifestations. The classic CD is only the tip of the CD iceberg, and many CD 
patients have only mild or none GI symptoms (Collin et al. 1997, Mäki et al. 1997, Bottaro et 
al. 1999, Dewar et al. 2005). The prevalence in Western countries varies between 0.4-2.0 % 
based on serologic screening studies (Not et al. 1998, Fasano et al. 2003, Mäki et al. 2003, 
West et al. 2003, Dubé et al. 2005, Lohi et al. 2007). The pattern of incidence has changed, 
with a greater proportion of cases being diagnosed later in adulthood (Dewar et al. 2005). The 
recent increase in the incidence and the prevalence of CD seems not to be based only on 
increased awareness of CD and screening for CD (Lohi et al. 2007). 
 
The clinical classification of CD is based on the presence of GI symptoms. The classic CD 
refers to presentations with diarrhoea, with or without malabsorption and malnutrition, 
whereas in atypical and/or silent CD, GI symptoms are absent or mild even though the patient 
might report other non-intestinal symptoms (Table 6). Diarrhoea occurs nowadays in less than 
50% of patients, whereas in the 1960´s it was present in almost all CD patients (Lo et al. 
2003). Weight loss is now an uncommon feature of CD. In contrast, 30% of CD patients are 
overweight at the time of diagnosis (Dickey et al. 1998). Overall the onset of symtoms seems 
to be milder and there is often a considerable latency before the diagnosis of CD (Dewar et al. 
2005).  
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Table 6. Clinical features of CD (Mäki et al. 1997, Dewar et al. 2005) 
 Classic CD 
 
Atypical or silent CD 
GI-related symptoms Diarrhoea / Steatorrhoea Loose bowels / obstipation 
 Abdominal distension Flatulence 
 Abdominal pain Abdominal pain (mild) 
  Abdominal distension (mild) 
   
Malabsorption related  Lethargy Anaemia 
symptoms Failure to thrive Osteopenia/ osteoporosis 
 Anaemia  
 Osteoporosis  
 Weight loss       
 Short stature       
        
Other symptoms Lymphoma Neurological problems 
  Infertility 
  Other autoimmune disorders 
  Dental enamel defects 
  Aphtous stomatitis 
       Arthralgia and arthritis 
  Hepatological problems 
    
 
Individuals with positive CD-specific serum antibodies, but with normal or minimally 
abnormal small bowel biopsy examination, have latent CD. The natural course of latent CD is 
unknown, but some individuals have been reported to develop CD with villous atrophy and 
clinical manifestations (Mäki et al. 1991, Collin et al. 1993, Högberg et al. 2003, Salmi et al. 
2006a).  
 
One explanation for the heterogeneity of symptoms of CD might be that the pathologic lesion 
of CD in small intestine develops gradually starting from proximal part of the small intestine 
and reaching finally the distal part. As a concequence, absorption in the small intestine is 
impaired. However, as the small intestine has a considerable functional reserve, many 
individuals with CD have few or no symptoms and no clinical evidence of malabsorption. 
Clinical presentation depends on the proportion of the small intestine affected, sensitivity to 
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gluten, the amount of gluten ingested, age, as well as other unknown factors (Dewar et al. 
2005). The genes causing CD may, at least in part, explain different expressions of CD. So 
far, the dose of the HLA DQ2 haplotype or the DQB1*0201 allele has been proposed to 
contribute to clinical features of CD (Table 2). 
  
The mortality rate of CD patients exceeds that in the general population by a factor of 1.9-3.8; 
mainly due to malignant diseases (Logan et al. 1989, Cottone et al. 1999, Corrao et al. 2001, 
Catassi et al. 2005). The reduction in excess mortality after 1-5 years on GFD suggests that 
GFD has a protective effect against malignant disease in CD patients (Collin et al 1996, 
Catassi et al. 2005, Viljamaa et al. 2006).  
 
2.5.2   Clinical features of dermatitis herpetiformis 
DH is a cutaneous manifestation of CD, which usually erupts in adulthood. DH expresses 
with intensely pruritic papulovesicles and excoriations on the elbows, knees, buttocks, and 
scalp. Virtually all DH patients have at least minor changes in small bowel mucosa at the time 
of DH diagnosis, and about 20% of DH patients have a complete flattening of villi (Marks et 
al. 1966, Fry et al. 1969, Reunala et al. 1984, Zone 2005). Clinically, 10-20% of DH patients 
with CD have classic symptoms of CD, 20% have atypical symptoms, and at least 60% do not 
have GI symptoms of CD (Zone 2005). DH, as well as the associated enteropathy, is 
recovered with GFD. Dapsone improves DH for the period the medicine is used, but not the 
intestinal lesion (Reunala et al. 1977). 
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2.5.3 Diagnosis of coeliac disease and dermatitis herpetiformis  
2.5.3.1   Small bowel biopsy 
The first diagnostic criteria for CD were defined in 1969 by an expert board of the European 
Society for Paediatric Gastroenterology and Nutrition (ESPGAN). These criteria were 
modified in 1990 (Walker-Smith et al. 1990). The diagnosis of CD is based on typical 
histological changes seen in small bowel mucosal biopsy specimens, and on improvement of 
histological lesions or clinical symptoms or both on GFD. The biopsies are obtained from the 
proximal part of small bowel usually by esophago-gastro-duodenoscopy (EGD), sometimes 
by a capsule technique or by push enteroscopy. Several well-oriented (not tangential) biopsies 
of adequate size should be taken because CD lesions might be patchy (Dewar et al. 2005). An 
intestinal biopsy should be undertaken if serological analysis is suggestive for CD or if 
serological tests are negative, but clinical suspicion is high. Duodenal biopsies should be 
taken routinely in EGD done for any reason, because the endoscopic appearence is often 
normal in CD and the clinical pattern of CD is heterogenous (Dickey et al. 2001, Collin et al. 
2002).  
 
The histological lesion related to CD develops gradually (Roy-Choudhury et al. 1966, Marsh 
1992) (Figure 4). First there is an infiltrative (Marsh I) lesion, which comprises normal 
mucosal architecture with increased level of IELs. After that there is a hyperplastic (Marsh II) 
lesion, which is similar to Marsh I lesion, but with the addition of enlongated crypts. After 
that a destructive (Marsh III) lesion developes, which correlates with classic villous atrophy 
of CD. The villous atrophy has been further devided to partial (Marsh IIIa), subtotal (Marsh 
IIIb), and total (Marsh IIIc) villous atrophy (Rostami et al. 1999). Finally, a hypoplastic 
(Marsh IV) atrophy of mucosa might develope. The Marsh IV stage has been suspected to be 
a predisposing stage for EATL (Marsh 1992).  
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Figure 4. Development of the histological lesion of CD according to Marsh (1992). 
 
A histological villous atrophy (Marsh III) is the criterion for the diagnosis of CD, although 
this requirement probably overlooks many subjects who are actually gluten-sensitive (Collin 
1999). On the other hand, although CD is the most common reason for villous atrophy in the 
small intestine, some other conditions must be borne in mind in differential diagnosis of CD, 
especially in cases with negative CD-specific serology and/or with mild mucosal changes. 
Conditions to be considered include autoimmune enteropathy, Crohn´s disease, collagenous 
sprue, infective gastroenteritis, bacterial overgrowth, giardiasis, tuberculosis, tropical sprue, 
Whipple´s disease, lactose intolerance, soya protein intolerance and other food allergies, 
anorexia nervosa, ischemic enteritis, Zollinger-Ellison syndrome, intestinal lymphoma, 
hypogammaglobulinemia, human immunodeficiency virus enteropathy, and other 
immunodeficiency states (Dewar et al. 2005). 
 
2.5.3.2   Skin biopsy 
A skin biopsy to detect DH is performed from normal-appearing, perilesional skin. 
Characteristic finding in DH is the presence of granular immunoglobulin (Ig)-A in dermal 
papillary tips (Van der Meer 1969).  
Marsh I Marsh II Marsh IIIa Marsh IIIb-c Marsh IV
Intraepithelial lymphocyte (IEL)
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2.5.3.3   Serological testing 
Positive serological tests support the diagnosis of CD, but are not required for the diagnosis. 
On the other hand, the diagnosis of CD can not be based only on positive serology. Similarly, 
negative serology does not exclude CD. However, especially in the absence of positive 
serology, other causes of villous atrophy must be considered in the differential diagnosis. The 
correlation of the presence of positive antibodies with the degree of villous atrophy is 
controversial. In some studies, serological tests have been negative in patients with partial 
villous atrophy (Rostami et al. 2000, Abrams et al. 2004), whereas in a Finnish study EMA 
was negative in the case of advanced CD (Salmi et al. 2006b). Positive serological tests 
normalise during GFD and can thus be used as a part of a follow-up programme of CD 
patients although serological tests seem not to be perfect to recognise villous lesions during 
GFD (Sategna-Guidetti et al. 1993, Kaukinen et al 2002b). In addition, serological tests can 
be used as a screening test for CD in individuals with GI symptoms and in certain high-risk 
groups (Collin 2005). 
 
EMA and tTG IgA-antibodies are the most sensitive and specific serological tests available 
for CD. Sensitivity of EMA-IgA varies between 86-100% and specificity between 97-100%, 
and sensitivity of tTG-IgA varies between 77-100% and specificity between 83-100% (Hill 
2005). The guinea pig protein tTG is clearly less sensitive than is the human recombinant 
protein tTG (Hill 2005).  Sensitivity and specificity of IgA-antigliadin antibodies (AGA) have 
been not only highly variable, but also generally lower than those for EMA and tTG 
(sensitivity 52-100%, specificity 71-100%) with sensitivity over 90% in 7 of 26 studies and 
specificity over 90% in 19 of 26 studies in a meta-analysis involving 1996 patients with CD 
and 2841 controls (Hill 2005).  Antireticulin antibodies (ARA) are currently not used mainly 
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because of low sensitivity (42-100%) (Collin 1999). IgG-antibodies should be used in 
diagnostic purposes in the case of selective IgA-deficiency (Hill 2005). Standardisation of 
antibody tests between different laboratories is important. Human recombinant tTG-IgA 
antibody test is probably the best test for the screening of CD, as it is easiest to perform. In 
addition, it has good sensitivity and specificity (Sulkanen et al. 1998b), and it is less observer 
dependent and cheaper than EMA (Collin 2005). In future, the deamidated gliadin peptide 
antibody test might be useful in detecting CD (Kaukinen et al. 2007). 
 
2.5.3.4   HLA genotyping 
Because over 99% of CD patients share at least one of the CD associated HLA alleles (Karell 
et al. 2003), the HLA genotyping can be used in certain circumstances to exclude the 
possibility of CD (for example in patients with equivocal biopsy results or negative 
serological test, or for patients already on GFD without a proper diagnosis of CD) (Kaukinen 
et. al 2002a). 
 
2.5.3.5   Other tests 
An increase in small bowel IELs, especially γδ T-cell receptor bearing cells, is typical, but not 
pathognomonic for CD (Collin 1999, Järvinen et al. 2003). Counting IELs is recommended in 
some borderline cases where histology is difficult to interpret. In the future the analysis of 
villous tip IELs or small-bowel mucosal transglutaminase 2 –specific IgA deposits might be 
helpful in detecting CD, especially at early stages of the disease and in patients with 
seronegative villous atrophy (Järvinen et al. 2004, Kaukinen et al. 2005, Salmi et al. 2006a). 
 
 
 
 
 48
2.5.4   Screening for coeliac disease 
Because the symptoms of CD are diverse or absent, screening for CD in some high-risk 
populations has been recommended. In contrast, population based screenings has not been 
accepted because the natural course and the complications of the silent CD are unclear, the 
diagnosis of CD and GFD might deteriorate the quality of life, adhearance to GFD might be 
low, the cost-effectiveness of the screening is unclear, and the possibility of false-positive 
antibody tests is higher than in the high-risk groups (Collin 2005, Cranney et al. 2005, 
Hoffenberg 2005). However, a recent study reported good quality of life and adherence to 
GFD in risk group screen -detected, asymptomatic patients with CD during a 14-year follow-
up (Viljamaa et al. 2005). 
 
The prevalence of CD in high risk populations is up to 20% in first-degree relatives, 3-15% in 
iron-deficiency anemia, 3-6% in type 1 diabetes, and 1-3% in osteoporosis (Dubé et al. 2005). 
In various autoimmune diseases, the risk of CD is about 5% (Collin et al. 2002). In some 
other conditions like infertility, neurological symptoms, elevated aminotransferases, liver 
failure, lactose intolerance, irritable bowel syndrome, and Down syndrome, the prevalence of 
CD is increased (Collin 2005, Dubé et al. 2005).  
 
Serological testing for CD antibodies is the most popular strategy to screen for CD. AGA and 
ARA tests have been widely used for screening previously, but recently the benefits of EMA 
and tTG tests have been noted. However, serological screening misses some cases of CD 
(Rostami et al. 1999, Dickey et al. 2000, Tursi et al. 2001, Abrams et al. 2004). Screening by 
EGD and duodenal biopsies is more reliable, but as EGD is an invasive and expensive 
method, it is saved for situations of high clinical suspicion of CD. Sometimes even EGD 
misses CD because of bad orientation or small size of duodenal mucosal biopsies or patchy 
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duodenal lesions of CD (Dewar et al. 2005). Genotyping for the HLA-alleles associated with 
CD could be used to exclude the possibility of CD (when negative) (Csizmadia et al. 2000, 
Kaukinen et al. 2002a, Hadithi et al. 2007), but it has not been studied in this purpose in 
family-based studies. In contrast, an identification of HLA risk allele does not help much in 
the screening, because most individuals carrying the CD-associated HLA-alleles will never 
develop CD (Liu et al. 2002). The best timing of screening is unclear in asymptomatic high-
risk individuals. 
 
2.5.5   Treatment of coeliac disease  
At present, the only available treatment for CD is life-long adherence to a strict GFD. 
However, the compliance to GFD is not perfect in a large proportion of patients (Sollid et al. 
2005a). In many countries, the availability of gluten-free products is not good, and the 
products are more expensive than gluten-containing counterparts. Recent advances in 
understanding of the pathogenesis of CD have given rise to the development of potential new 
therapies, e.g. oral enzyme supplementation, transamidation of wheat flour, tTG inhibitors, 
HLA-DQ2-blockers, cytokine therapy, selective adhesion molecule inhibition, and others 
(Sollid et al. 2005a, Gass et al. 2007, Gianfrani et al. 2007). 
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3. AIMS OF THE STUDY   
 
The general aim of this study was to investigate the genetic background and phenotype 
characteristics of CD in Finnish families. In addition, different screening methods for CD in 
families were investigated. The specific aims of different studies were: 
  
1. To perform a genome-wide scan to identify susceptibility loci for CD. 
 
2. To investigate whether a gene dose effect of the DQA1*0501 allele or the DQB1*0201 
allele contributes to the severity of CD. 
 
3. To investigate whether HLA genotyping is useful in the evaluation of the risk of CD in 
first-degree relatives of patients with CD. 
 
4. To compare different screening methods for CD with special emphasis on the initial HLA 
genotyping in the first-degree relatives. 
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4. SUBJECTS AND METHODS 
 
4.1    Subjects and study design 
 
4.1.1    Index patients 
 
All subjects participating in this study were Finnish. The prevalence of CD in Finland has 
been estimated to be about 1:270 (Collin et al. 1997) or even 1:100-1:50 (Mäki et al. 2003, 
Lohi et al. 2007). The Kuopio University Hospital region in Eastern Finland covers a 
population of 250 000. Thus, the expected number of CD patients in this region is about 900-
5000. The index patients for this study were selected from CD and DH patients diagnosed 
and/or treated at Kuopio University Hospital until 1996. The criteria for a selection was a 
definite diagnosis of CD and/or DH according to the following criteria: Small bowel mucosal 
biopsy with total, subtotal, or severe partial villous atrophy with crypt hyperplasia, or skin-
biopsy-proved DH. In severe partial villous atrophy also positive AGA and/or EMA and/or 
ARA and/or biopsy-proved DH was required. The majority of patients had a follow-up biopsy 
demonstrating mucosal recovery on a GFD, and all patients recovered from symptoms of CD 
and/or DH. 
 
Altogether 428 patients (330 CD and 98 DH) fulfilled the diagnostic criteria (Walker-Smith et 
al. 1990). The patients with CD represented mainly the classic form of CD rather than the 
asymptomatic or atypical form. To find CD families for a genome-wide scan, the relatives of 
the index patients were investigated as described below. 
 
4.1.2    Study protocol 
The index patients were sent a questionnaire asking the CD and DH -status of their first and 
second -degree relatives. The response rate was 71% (304/428) (Figure 5). 
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Questionnaire sent to 
428 subjects  
(330 CD, 98 DH) 
Response 
n=304
Families included  
in the genome-wide 
scan 
n=60
Alive 
n=382 
Examined in our study 
n=208 
Non-affected 
n=163 
Excluded     
    n=6 
Final study population (families)  
                  n=54
Probands 
  n=54 
1st-degree relatives     
           n=467 
2nd-degree relatives  
(CD affected) 
n=10 
CD diagnosed 
before our study 
n=37 
Refused 
n=137 
 CD 
n=45 
Figure 5.  Flowchart of the Study protocol. 
 53
First, those families including at least two subjects with CD were investigated. All first-
degree relatives of patients with CD (parents, siblings, and offspring) were invited to an 
examination, which included EGD with duodenal biopsies, a skin biopsy, CD antibody-
testing, other laboratory tests, and a questionnaire about the symptoms. The diagnoses of CD 
of family members, who had been diagnosed before the present study, were re-evaluated by 
scrutinizing the medical records. A venous blood sample for DNA analyses was obtained 
from the index patients and from all relatives who participated in this study. For those who 
refused from EGD, CD antibody testing and a blood sample for DNA were offered. If a 
relative was diagnosed to have CD also the first-degree relatives of that individual were 
invited to examination. 
 
Secondly, to get enough families for a genome-wide screening, those families where the index 
patient was the only subject having CD were investigated. Siblings of the index patients were 
offered antibody tests for CD (AGA, ARA, EMA). If any of the antibodies were positive, the 
sibling was examined as described above (duodenal and skin biopsies, blood samples, 
questionnaire). If the sibling was found to have CD, the other first-degree relatives were 
similarly examined. All family members were clinically examined in 1996-1999.   
 
4.1.3    Families participating in the genome-wide scan (Study I)     
Any family to be included in the genome-wide scan to identify susceptibility genes for CD, 
had to have at least two siblings with CD fullfilling the diagnostic criteria mentioned above. 
However, DH without villous atrophy was not sufficient for the diagnosis of CD and they 
were excluded. A total of 60 families fullfilled the criterion. Based on the genome scan, six 
families were excluded (monozygote twins in one family, half-siblings in two families, and 
Mendel/sample errors in three families). Thus, the final study population consisted of 54 
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families including 146 CD patients (41, 10, and 3 families had 2, 3, and 4 affected siblings, 
respectively). Altogether 146 CD patients and 104 healthy first-degree relatives were included 
in the genome-wide scan.  
 
4.1.4    Coeliac disease patients participating in the Study II 
The study population of Study II consisted of CD patients (n=146) who were included in the 
genome-wide scan. Two of CD patients were excluded because of slight partial villous 
atrophy with positive CD antibodies, thus 144 CD patients (127 with CD, 88.2%, and 17 with 
CD and DH) were included. Mean age at the diagnosis of CD was 42.5 +/- 15.5 (range 1-79) 
years. Most of CD patients (94.4%) were adults (>17 years old) at the time of diagnosis 
(59.7% women, 40.3% men).  
 
4.1.5    Families participating in the Study III 
The study population consisted of the aforementioned 54 CD families. The probands (n=54) 
and all first-degree relatives examined (n=245) were included (82 affected and 163 non-
affected). The second-degree relatives of the probands were excluded. The mean age of CD 
patients at diagnosis was 43.7±14.7 (range 1-79) years; 95.6% of them were adults at 
diagnosis. Of CD patients, 58.8% were women. The characteristics of the first-degree 
relatives are shown in Table 7. 
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4.1.6    First-degree relatives participating in the Study IV 
The study population consisted of those first-degree relatives of the aforementioned 54 CD 
families who had been examined in this study (n=208). First-degree relatives who were 
diagnosed to have CD before this study (n=37) were excluded. In addition, 19 of the first-
degree relatives were excluded because they lacked a questionnaire about GI symptoms. 
Thus, the final study population included 189 subjects (42 subjects with CD and 147 first-
degree relatives without CD). The mean age of the study population was 45.0±17.1 (range 8-
77), and 60.3% of them were women. 
 
4.2    Methods 
4.2.1    Esophago-gastro-duodenoscopy 
EGD was performed with an Olympus GIF-20 or an Olympus GIF-30 gastroscope (Tokyo, 
Japan) (adults) or with an Olympus GIF-XQ30 gastroscope (Tokyo, Japan) (children under 10 
years old). The biopsies were taken with an Olympus FB-13K jumbo forceps (Tokyo, Japan) 
(adults) and an Olympus FB-24K forceps (Tokyo, Japan) (children under 10 years). 
Altogether seven biopsies were taken from the proximal small intestine (five from the distal 
part of duodenum and two behind the bulbar part of duodenum). Two distal-duodenal biopsies 
and two post-bulbar biopsies were used for histological evaluation.  
 
4.2.2    Duodenal biopsies 
Endoscopic duodenal biopsy specimens were fixed in 10% buffered formalin and processed 
by standard methods. The staining method used was van Gieson´s (Bradbury et al. 1982). 
Specimens were oriented with the aid of a dissecting microscope to get well-oriented villi in 
the histologic sections. The degree of crypt hyperplastic villous atrophy was graded as total, 
subtotal, partial (severe or slight), or normal (Roy-Choudhury et al. 1966, Janatuinen et al. 
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1995). No villous projections from the surface were seen in total atrophy, and in subtotal 
atrophy villi were almost completely absent. In slight partial atrophy, some villi were slightly 
broadened and shortened, whereas in severe partial atrophy villi were more damaged and 
almost corresponded to that seen in subtotal atrophy. The same pathologist conducted all 
duodenal histopathological examinations and re-evaluated all duodenal biopsy specimens 
taken before this study. 
 
4.2.3    Skin biopsy 
A skin biopsy was taken from uninvolved skin using a Stiefel-punch (∅ 3mm) under local 
anesthesia (4-5 ml Lidocain 10mg/ml –Adrenalin). After removal, skin biopsy specimens 
were embedded in Cryomatrix (Shandon Inc., Pittsburgh, PA, US) and frozen in isopentane 
cooled with a mixture of absolute ethanol and dry ice. Cryosections of 4 µm thickness were 
cut into 6 uncoated slides and stored at -20°C until stained. The slides were stained with 
antibodies directed towards IgA, IgG, IgM, fibrinogen and complement C3c. Also a control 
antibody against IgA+IgG+IgM+kappa+lambda was applied. All antibodies were FITC-
conjugated and purchased from DAKO (Glostrup, Denmark). All slides were stained in 
Techmate 500 automated immunostainer (DAKO, Glostrup, Denmark) using the direct 
immunofluorescence (IF) method. The slides were examined with a Leitz Dialux 22 
microscope equipped with an epifluorescence system (Leica, Nussloch, Germany).  Antibody 
staining results were marked as - (negative), + (slightly positive), ++ (clearly positive), +++ 
(strongly positive). A granular deposition of IgA in the dermal papillae (clearly or strongly 
positive IgA antibody staining) was the diagnostic criterion used for DH. All biopsies were 
examined by the same investigator.  
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4.2.4    Serology 
All antibody tests of the family members were performed in the same laboratory (Institute of 
Medical Technology, University of Tampere, Finland). For those family members, who were 
diagnosed to have CD before this study, the antibody parameters were recorded at the time of 
diagnosis if available. 
 
IgA-class EMA were measured by means of indirect IF method, using unfixed cryostat 
sections of full-term human infant umbilical cord as antigen (Ladinser et al. 1994, Volta et al. 
1995, Sulkanen et al.1998a). IgA-class ARA were examined by using a composite block of 
rat kidney, liver, stomach, and heart as antigens (Hällstöm 1989). Patient sera were screened 
for IgA-class EMA and ARA at dilutions of 1:5 and 1:50 with fluorescein isothiocyanate-
conjugated monospecific goat antiserum to human IgA (Kallestad Diagnostics, Chaska, 
Minn., USA). Positive sera were further titrated 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000, 
1:4000, and 1:8000. All dilutions of sera were made in phosphate-buffered saline, pH 7.2-7.4. 
Positive and negative controls were included in every test batch. Sections were examined by 
fluorescent incident light microscopy. EMA positivity included a specific honeycomb-like 
fluorescence around the smooth-muscle fibres in the muscularis mucosa of the vessels. The 
ARA test was considered positive when the characteristic R1-type ARA pattern was found. 
 
IgA- and IgG-class AGA were measured with a solid-phase enzyme-linked immunosorbent 
assay (ELISA) with a crude gliadin preparation as antigen, as previously described (Savilahti 
et al. 1983). The results were obtained from a standard curve established on the basis of 
dilutions of a positive reference serum and converted to concentrations of arbitrary ELISA 
units per millilitre (EU/ml). Patient and control sera with AGA in higher concentrations of 
EU/ml than known healthy controls (mean plus two standard deviations) used in the 
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laboratory were considered positive; the cut-off level was 0.2 EU/ml for IgA-class AGA and 
10.0 EU/ml (adults) and 15.0 EU/ml (children) for IgG-class AGA. 
 
4.2.5    Other laboratory tests 
A venous blood sample for laboratory tests (B-haemoglobin, mean cellular volume of 
erythrocytes, fS-iron, fE-folate, fP-calcium, S-albumin, S-IgA, S-IgM, S-IgG) was obtained 
from all subjects in this study. For those family members, who were diagnosed to have CD 
before this study, the laboratory parameters were recorded at the time of diagnosis if 
available. In addition, a blood sample (36 ml adults and 18 ml children under 10 years) for 
DNA analyses was taken.  
 
4.2.6    Questionnaire for symptoms 
A questionnaire for the symptoms and previous diseases was obtained. The symptoms were 
classificated as follows: 1. mild: not disturbing daily life, 2. moderate: disturbs daily life, but 
does not prevent from working, or 3. severe: prevents working, needs medication. For those 
family members, who were diagnosed to have CD before this study, the questionnaire was 
recorded if available.  
 
4.2.7    HLA genotyping    
DNA was prepared from blood leucocytes using the salting-out method (Miller et al. 1988). 
The presence of the DQ2 alleles DQA1*0501 and DQB1*0201 and the presence of the DR4 
allele DRB1*04 as well as control fragment AC-2 were identified by a rapid PCR-based 
identification method (Sacchetti et al. 1997). The following primers were used: DQA1*0501 
forward 5’-AGC AGT TCT ACG TGG ACC TGG GG-3’, DQA1*0501 reverse 5’-GGT 
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AGA GTT GGA GCG TTT AAT CAG A-3’, DQB1*0201 forward 5’-GCG GTG CGT CTT 
GTG AGC AGA AG-3’, DQB1*0201 reverse 5’-GGC GGC AGG CAG CCC CAG CA-3’, 
DRB1*04 forward 5’-GGT TAA ACA TGA GTG TCA TTT CTT AAA C-3’, DRB1*04 
reverse 5’-GTT GTG TCT GCA GTA GGT GTC-3’, AC-2 forward 5’-GCA GAG TAC CTG 
AAA CAG GA-3’ and AC-2 reverse 5’-CAT TCA CAG TAG CTT ACC CA-3’.  
 
Multiplex PCR reactions were carried out as follows:  
DQ2 alleles; The 11 µl reaction mixture consisted of 50 ng of genomic DNA, 3 pmol of each 
primer (DQA1*0501 forward and reverse, and DQB1*0201 forward and reverse), 10% buffer 
III with 20 mM of MgCl2 and pH of 8,0 (PCR Optimisation Kit: MBI Fermentas, Vilnius, 
Lithuania), 100 µM dNTPs and 0,13 units of DNA polymerase (recombinant Taq DNA 
polymerase; MBI Fermentas, Vilnius, Lithuania).  
DR4 alleles; The 10 µl reaction mixture consisted of 50 ng of genomic DNA, 6 pmol of each 
primer (DRB1*04 forward and reverse, and AC-2 forward and reverse as control primers), 10 
mM Tris-HCl (pH 8,8), 50 mM KCl, 1,5 mM of MgCl2, 0,1% Triton X-100, 100 µM dNTPs 
and 0,15 units of DNA polymerase (Dynazyme DNA polymerase; Finnzymes, Espoo, 
Finland). The PCR conditions were as follows: initial denaturation at 95°C for 5 minutes 
(min), followed by 30 cycles of denaturation at 94°C for 30 seconds (s), annealing at 60-64°C 
for 10 s, and extension at 72°C for 20 s; and a final extension at 72°C for 10 min. After PCR 
reaction the samples were run on 9% polyacrylamide gel stained in ethidiumbromide and 
photographed. The length of amplified PCR products were 144 bp in DQA1*0501 allele, 110 
bp in DQB1*0201 allele, 177 bp in DRB1*04 allele and 491 bp in control fragment (AC-2). 
 
The single-strand conformation polymorphism analysis (SSCP) method was used to separate 
heterozygous and homozygous DQ2 allele carriers (Orita et al. 1989). The following 
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previously published primers were used in PCR reactions: DQA forward 5’-GGT GTA AAC 
TTG TAC CAG T-3’, DQA reverse 5’-GTA GCA GCG GTA GAG TTG-3’ and DQB 
forward 5’-CAG ACA CAT CTA TAA CCG A-3’, DQB reverse 5’-CTC GTA GTT GTG 
TCT GCA-3’ (Clay et al. 1995).  SSCP reaction mixture of 6 µl consisted of 50 ng of 
genomic DNA, 3 pmol of each primer (DQA forward and reverse; DQB forward and reverse), 
10 mM Tris-HCl (pH 8.8), 50 mM KCl, 1.5 mM of MgCl2, 0.1% Triton X-100, 100 µM 
dNTPs, 0.14 units of DNA polymerase (Dynazyme DNA polymerase; Finnzymes, Espoo, 
Finland) and 0.55 µCi of α-33P dCTP (NEN Life Science Products, Boston, Massachusetts, 
US). The PCR conditions were as follows: initial denaturation at 94°C for 3 min, followed by 
30 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 45 s, and extension at 72°C 
for 30 s; and a final extension at 72°C for 10 min. The PCR products were first diluted 4-fold 
with 0.1% sodium dodecyl sulphate (SDS) and 10 mM EDTA and after that diluted (1:1) with 
loading mix (containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 
0.05% xylene cyanol). After denaturation at 98°C for 3 min, samples were immediately 
cooled on ice. A total of 3 µl of each sample was loaded onto a 6% non-denaturing 
polyacrylamide gel (acrylamide/N,N-methylene-bis-acrylamide ratio 49:1) containing 10% of 
glycerol. The runs were performed at two different gel temperatures: 38°C for 4 hours (h) and 
29°C for 5 h. The dried gels were autoradiographed at –20°C for one to five days. The results 
of the SSCP analysis were verified by sequencing genomic DNA from individuals with 
different SSCP patterns using ABI Prism BigDye Terminator Cycle Sequencing Ready 
Reaction Kits and ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, 
California, US). 
              
 
 
 62
4.2.8    Genome-wide scan 
Genomic DNA was extracted from peripheral blood lymphocytes from affected and 
unaffected family members. Parental DNA samples were typed when available: 17% of the 
families had both parents and 33% had one parent. Unaffected siblings were also typed in 
67% of the families missing both parental DNA samples. Genotyping was performed by use 
of a modified version of the Co-operative Human Linkage Center (CHLC) Human Screening 
Set/version 6.0 panel of polymorphic markers (Dubovsky et al. 1995). Specifically, the 
screening set comprised 312 fluorescently labelled genetic markers (Research Genetics) with 
average heterozygosity of .75 and average spacing between markers of 12 cM (Rioux et al. 
1998).  
 
PCR-reactions were set up with a robotic pipetting station (Rosys Robotic Systems) in thin-
walled 192-well polycarbonate plates (Corning Costar). Reactions were overlaid with light 
mineral oil (Sigma Chemical) and were amplified on custom-built thermocyclers (Intelligent 
Automation Systems), each accommodating 16 192-well plates. PCR products were then 
multiplexed into panels by pooling (average of eight markers/panel) based on allele-size range 
and fluorescent label. Aliquots of the multiplexed samples were mixed with either Tamra-
labelled GENESCAN 500 and GENESCAN 2500 (Perkin Elmer Applied Biosystems) or 
rhodamine-labelled MapMarkers (Bioventures) and then were run on ABI377 sequencers 
(Perkin Elmer Applied Biosystems) (Rioux et al. 1998). 
 
Fluorescent genotyping gels were analysed in an automated system developed at the 
Whitehead Institute/Massachusetts Institute of Technology (MIT) Center for Genome 
Research. The gels were tracked automatically and reviewed manually by use of the 
Bass/Grace gel-analysis system. Alleles were called automatically by use of software that 
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implements strict guidelines (to prevent miscalls due to leakage, mistracking, weak signal, or 
detector saturation) and that identifies alleles based on their characteristic response (including 
A+ and stutter bands). Sizes were determined automatically by comparison with the size 
standards loaded on every lane. Control genotypes were included on every gel, to ensure 
accurancy and reproducibility of allele calling. Gels, pedigrees, and markers with aberrantly 
large numbers of Mendelian-inheritance errors were re-examined carefully to monitor any 
systematic laboratory or sample mix-ups and to ensure that each fluorescent marker was 
producing a consistent assay. The automated genotyping system also was monitored 
frequently by comparison with manual genotype calls, to ensure consistent performance.  
 
The NPL analysis of data from the genomewide scan was performed with CD (with or 
without DH) as the phenotype using Genehunter 2.0. To establish appropriate thresholds for 
suggestive (i.e., the score expected to occur one time at random in a genomewide scan) and 
significant (i.e., the score expected to occur one time at random in 20 genomewide scans) 
genomewide linkage for this particular dataset, simulations were performed by generating 
artificial genotype data with identical family structures (Gensim computer program). These 
simulations matched our dataset with respect to marker density, marker informativeness, 
individuals genotyped, affected status, and fraction of missing data. These genome scan 
simulations were performed by generating random genotypes for pedigree founders and 
passing them on at random under the hypothesis of no linkage and using the recombination 
distances and marker density and heterozygosity of the actual dataset. Ungenotyped 
individuals remained so in the simulated data and missing genotype data was inserted at 
random at the rate at which it occurred in individuals available for genotyping. One thousand 
genome screens were generated at the genome scan marker density (one marker every 10 cM 
throughout). In this manner, the genomewide thresholds for suggestive and significant linkage 
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resulted in Z scores of 1.9 and 2.7, respectively. These empirical thresholds are lower than the 
theoretical thresholds 2.9 and 4.1, respectively, reported by Lander and Kruglyak (1995), 
since the theoretical thresholds are based on an infinitely dense genetic map, a particular 
family structure and perfect information. 
 
Association testing was performed in this sample by randomly selecting a single discordant 
sib-pair from each family and performing a sib-TDT (in this form a pure test of association). 
These results were combined with other TDT and case-control studies by reformatting the 
results of each study as a mean, observed, and variance on the number of risk alleles 
transmitted (i.e., in studies using trios) or found in cases (i.e., in case-control studies). A 
combined Z score and P value were then computed using summation. Odds ratios (ORs) and 
pooled ORs were computed using the logit method as described by Morris and Gardner 
(1988). 
 
4.2.9    CTLA-4 genotyping 
The exon 1 polymorphism (+49*A/G) of the CTLA-4 gene was typed using standard PCR 
allele specific dot blot hybridisation with PCR primers (forward 5´-GCTCTACTTCC 
TGAAGACCT-3´ and reverse 5´-AACCCAGGTAGGAGAAACAC-3´; 35 cycles of 30 s at 
94°C for denaturing, 30 s at 50°C for annealing, and 60 s at 72°C for extension) and detection 
oligonucleotides (5´-AACCTGGCTGCCAGGACC-3´ and 5´-AACCTGGCTACCAGGACC-
3´) (Djilali-Saiah et al. 1998). The presence of the G allele of CTLA-4 position 49 
polymorphism was confirmed by digestion of the PCR product with the restriction 
endonuclease BbvI and visualisation of the fragments on 2.5% agarose gels stained with 
ethidium bromide. 
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Allele and phenotype frequencies were determined. ORs were calculated according to 
Woolf´s formula, and the p value was defined by chi-square (χ²) analysis using a 2x2 or 2x3 
contingency table, or Fisher´s exact test where appropriate. A value of p<0.05 was considered 
significant. 
 
4.2.10    Statistical methods    
All statistical analyses were performed with the SPSS for Windows program (version 11.0 or 
11.5, SPSS Inc., Chicago, Illinois, USA). The results are given as mean±SD, or percentages. 
The effect of the DQA1*0501 and DQB1*0201 alleles on the grading of villous atrophy at the 
time of diagnosis and after one year of GFD in Study II was tested with the χ² test. 
Furthermore, the differences in GI symptoms between the different study groups in Study IV 
were tested with the χ² test. A p-value less than 0.05 was considered statistically significant.  
 
The differences in variables (age at diagnosis, laboratory parameters, GI symptoms) among 
the CD patients with different HLA genotypes and haplotypes in Study II were tested with the 
linear regression with the program ASSOC (S.A.G.E., version 2.2, Ohio, US) (George et al. 
1987). The ASSOC program allows the quantitative trait to have familial correlation among 
individuals. The likelihood for the pedigree is computed with a linear regression model in 
which the quantitative trait is the dependent variable and genetic variation and discrete and/or 
continuous covariates are independent variables. Residual variation is modelled assuming an 
additive polygenic pattern of correlation among relatives. By the use of this model, the 
likelihood for each pedigree was maximised twice, with and without the genetic HLA 
polymorphism in the model. The difference in natural logarithms of these 2 maximised 
likelihoods follows the chi-square distribution from which the corresponding p-value is taken 
with 2 degrees of freedom (three groups of HLA genotypes). Linkage disequilibrium between 
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the variants in the Study II was estimated using the program EH 
(http://linkage.rockefeller.edu/ott/eh.htm).  
 
4.3    Approval of the Ethics Committee 
The study was approved by the Ethics Committee of the Kuopio University Hospital and the 
University of Kuopio. All subjects gave informed consent and all samples were collected 
according to the World Medical Association Declaration of Helsinki (WMA, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67
5. RESULTS 
 
5.1 Genome-wide scan to identify susceptibility loci or genes for coeliac disease 
 (Study I) 
In a multipoint NPL analysis of the genome-wide scan two chromosomal regions were found 
to have significant evidence of linkage to CD (6p; peak NPL 3.0 at D6S1281, p=0.0016, and 
2q23-32; peak NPL 2.8 at D2S1776, p=0.003), and one region had suggestive linkage to CD 
(10p; peak NPL=1.93 at D10S674; p=0.028) (Figure 6).  
 
 
Figure 6.   Multipoint linkage analysis results for the genome-wide scan for predisposing 
genes for CD (I). NPL scores were calculated using the Genehunter 2.0 software. Tick marks 
on the horizontal axis indicate the positions of the microsatellite markers, the vertical axis 
indicates the NPL score, and the thick line shows the NPL score along each chromosome. 
Genome-wide thresholds for suggestive and significant linkage were calculated by simulation 
to be 1.9 and 2.7, respectively (Rioux et al.2000). 
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To investigate the possibility that the linkage peak at 6p is due to presence of the HLA DQ2 
risk alleles, the DQ2 alleles were genotyped. Altogether 91% of the CD patients had at least 
one copy of the HLA DQ2 risk haplotype, while only 40% of unaffected individuals had one 
or more copies of the risk haplotype. In addition, the HLA risk haplotype showed a significant 
association with the CD phenotype (Z score=6.94; p=1.96x10−¹²), indicating that the DQ2 
alleles (or other alleles/genotypes in strong linkage disequilibrium with DQ2) contribute to 
CD susceptibility. 
Because the 2q23-32 region contains the CTLA-4 gene, a gene first reported by Djilali-Saiah 
et al. (1998) to have the A allele (the +49*A/G dimorphism) associated with CD, all study 
subjects were genotyped for this variant. Sib-TDT analysis did not provide significant 
evidence for an association of this allele with CD. However, when our results were combined 
with three additional follow-up studies, that reported the actual association data for this 
specific variant (Clot et al. 1999, Naluai et al. 2000, Mora et al. 2003), the combined results 
from 506 families resulted in a pooled one-tailed p-value of 0.002 and an OR of 1.29 (95% 
1.09-1.52), potentially replicating the original finding. 
 
5.2    Gene dose effect of the DQA1*0501 allele and the DQB1*0201 allele on the severity 
 of coeliac disease (Study II)       
Genotype frequencies of the CD risk alleles in patients with CD were as follows:  
DQA1*0501; no risk alleles in 8.3% (n=12), one risk allele in 72.9% (n=105), two risk alleles 
in 18.8% (n=27) of subjects; and DQB1*0201; no risk alleles in 6.3% (n=9), one risk allele in 
71.5% (n=103), and two risk alleles in 22.2% (n=32) of the subjects. These variants were in 
strong linkage disequilibrium (D’=0.90, p<0.001). Of all patients, 13.2% (n=19) were 
homozygous for both alleles and 5.6% (n=8) had neither of the alleles.  
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The DQ2 heterodimer frequencies of CD patients were as follows: not present in 9.0% (n=13; 
no DQA1*0501 nor  DQB1*0201 allele n=8, only one DQA1*0501 allele n=1, only one 
DQB1*0201 allele n=4), heterozygote in 77.8% (n=112; one DQA1*0501 and one 
DQB1*0201 allele n=91, two DQA1*0501 alleles and one DQB1*0201 allele n=8, one 
DQA1*0501 allele and two DQB1*0201 alleles n=13) and homozygote in 13.2% (n=19) of 
subjects.  
 
A significant gene dose effect of the number of the DQB1*0201 alleles on the grading of 
small bowel mucosal villous atrophy at the time of CD diagnosis was found (p=0.011, Figure 
7). Similarly, homozygosity for the DQB1*0201 allele was associated with a slower recovery 
rate of duodenal villous atrophy after one year therapy with GFD (p=0.041, Figure 8). 
Furthermore, younger age at the time of CD diagnosis was associated with the gene dose 
effect of the number of the DQB1*0201 allele (p=0.036). The age at diagnosis was 53±15, 
43±15, and 38±14 years in non-allelic, heterozygous, and homozygous subjects for 
DQB1*0201, respectively. In contrast, the number of the DQA1*0501 alleles was not 
associated with villous atrophy or the age at CD diagnosis.  
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Furthermore, homozygosity for the DQB1*0201 allele (p=0.010) was associated with lower 
blood haemoglobin level at the time of diagnosis, even after adjustment for the severity of 
villous atrophy and gender (p=0.036). There were no significant differences in mean cellular 
volume of erythrocytes, serum iron, folate of erythrocytes, plasma calcium, and serum 
albumin values among different genotype groups although serum iron and folate of 
erytrocytes tended to be lower in subjects homozygous for the DQB1*0201 allele. In addition, 
homozygosity for the DQB1*0201 allele was associated with severe abdominal pain 
(p=0.015), severe diarrhoea (p=0.048), and with a more frequent stool frequency (p=0.050) at 
the time of CD diagnosis, but the homozygosity for the DQA1*0501 allele was associated 
only with severe abdominal pain (p=0.040).  
 
Because of the linkage disequilibrium between the DQA1*0501 and DQB1*0201 alleles, we 
next analyzed the effect of the DQ2 heterodimer on the severity of CD. A significant 
association of homozygosity of the DQ2 heterodimer compared to those without the DQ2 
heterodimer was found with a more severe villous atrophy (p=0.006) and a lower value of 
blood haemoglobin (p=0.015) at the time of diagnosis. In contrast, the gene dose effect of the 
DQ2 heterodimer was not associated with the severity of villous atrophy after one year on 
GFD (p=0.814), age at diagnosis (p=0.207), stool frequency (p=0.106), degree of diarrhoea 
(p=0.238), degree of abdominal pain (0.059), or level of the other laboratory values than 
blood haemoglobin.  
   
5.3    HLA genotyping in the evaluation of the risk for coeliac disease in the first-degree 
relatives (Study III) 
Of all first-degree relatives investigated (n=245), 17.6% (n=43) did not carry any of the CD 
risk alleles (Table 8). Altogether, 5.9% of the parents of probands, 15.7% of the siblings of 
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probands, and 25.8% of the offspring of probands did not have any of the CD risk alleles. Of 
the CD probands (n=54) and the CD affected first-degree relatives (n=82), all except one 
individual (99.3%) carried at least one of the CD associated alleles DQA1*0501, DQB1*0201, 
or DRB1*04. Most of the affeceted first-degree relatives (n=73, 89%) carried both the 
DQA1*0501 allele and the DQB1*0201 allele. Altogether 7.3% (n=6) carried only the 
DRB1*04 allele, but not the DQA1*0501 allele or the DQB1*0201 allele.  
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5.4  Combined role of HLA genotyping, serological tests, and symptoms in the 
 screening for coeliac disease among the first-degree relatives (Study IV) 
Altogether 45 (21.6 %) of the screened individuals were diagnosed to have CD. Of those first-
degree relatives (n=163), who did not have CD, 42 (25.8%) carried none of the HLA alleles 
associated with CD.  
 
GI symptoms, except for abdominal pain, occurred significantly more frequently in those 
first-degree relatives who were diagnosed to have CD than in the non-affected relatives (Table 
9). However, abdominal complaints were common both in CD patients and in healthy 
subjects. Furthermore, 14.3 % (n=6) of the subjects with CD reported no GI symptoms, and 
14.3 % (n=6) experienced only one of the symptoms. Moreover, 47.6 % (n=20) of affected 
first-degree relatives with CD, who had more than one of the symptoms, reported only mild 
symptoms, and none of them had severe symptoms. There was no statistical difference in GI 
symptoms among non-affected relatives who had the HLA status typical for CD and non-
affected relatives who did not have the HLA status typical for CD (Table 9).  
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Table 9.  Gastrointestinal symptoms in the first-degree relatives of patients with CD (IV). 
 
 
 
¹ Carries at least one of the following alleles: DQA1*0501, DQB1*0201, or DRB1*04 
² Carries none of the following alleles: DQA1*0501, DQB1*0201, or DRB1*04  
*    p<0.001 between Groups A (= CD) and Groups B+C (= no CD) 
**  p=0.005 between Groups A (= CD) and Groups B+C (= no CD) 
†    p=0.004 between Groups A (= CD) and Groups B+C (= no CD) 
 
 
Symptom Group A 
CD;  
diagnosed by 
screening 
       n=42 
 
       n (%) 
Group B 
No CD;  
HLA risk alleles 
for CD¹  
       n=110 
 
       n (%) 
Group C 
No CD;  
No HLA risk alleles  
for CD²  
       n=37 
 
       n (%) 
Diarrhoea *         
      none 17 (40.5) 85 (77.3) 25 (67.6) 
      mild  25 (59.5) 21 (19.1) 11 (29.7) 
      moderate  0 (0) 3 (2.7) 1 (2.7) 
      severe  0 (0) 1 (0.9) 0 (0) 
Abdominal pain    
      none 22 (52.4) 70 (63.6) 29 (78.4) 
      mild 18 (42.9) 38 (34.5) 8 (21.6) 
      moderate 2 (4.8) 2 (1.8) 0 (0) 
      severe 0 (0) 0 (0) 0 (0) 
Abdominal bloating **    
      none 11 (26.2) 51 (46.4) 19 (51.4) 
      mild 20 (47.6) 51 (46.4) 12 (32.4) 
      moderate 11 (26.2) 8 (7.3) 6 (16.2) 
      severe 0 (0) 0 (0) 0 (0) 
Flatulence †    
      none 7 (16.7) 35 (31.8) 8 (21.6) 
      mild 21 (50.0) 65 (59.1) 21 (56.8) 
      moderate 14 (33.0) 10 (9.1) 8 (21.6) 
      severe 0 (0) 0 (0) 0 (0) 
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EMA and ARA were negative in 16.7% (n=7) and 23.8% (n=10) of CD patients, respectively. 
EMA and ARA were positive in 2.7% (n=3) of the non-affected first-degree relatives; all of 
whom carried HLA risk alleles for CD. EMA and ARA were negative in most of the non-
affected first-degree relatives who had HLA status associated with CD (97.3%). AGA was 
negative in 4.8% (n=2) of CD patients. AGA was positive in 32.0% (n=47) of non-affected 
relatives, of whom 16 individuals (34.0%) did not carry any of the HLA risk alleles associated 
with CD.  
 
The comparison between different screening strategies for CD in the first-degree relatives 
based on our study results is shown in Table 10.  If the HLA risk allele genotyping is done 
first and if relatives who carry none of the HLA risk alleles associated with CD are excluded 
from further screenings, the need of EGD is reduced by about 20 %. 
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6. DISCUSSION 
6.1    Subjects and Study design 
The advantage of the Finnish population in genetical studies is a relatively homogenous gene 
pool, originating mainly from Southern (European) and Eastern (Asian) immigration about 
2000 years ago (de la Chapelle 1993, Kittles et al. 1998). In addition, the environmental and 
cultural variability is low when compared to many other populations. When added with high 
co-operativeness of Finnish subjects with medical research and the high standard of the 
medical and population based records, the Finnish population has proved to be valuable in 
genetical studies, especially in finding single gene defects. However, the value of the Finnish 
population in studies of complex diseases, such as CD, is less clear (Liu et al. 2002). At the 
time, when our study was started no genome-wide screenings for CD had been published. 
  
Our results might have been biased by the fact that our study population consisted of multi-
affected families. The prevalence of CD in the first-degree relatives of our families was 
17.6% for all the first-degree relatives (21.5 and 33.5% for all first-degree relatives alive and 
for the first-degree relatives having duodenal biopsies, respectively) (Table 7). In addition to 
high prevalence of CD in our families as compared to most previously published family-based 
studies (Table 1), the genetic background might differ between the families with multiple 
cases of CD and sporadic cases of CD. The frequency of the HLA alleles associated with CD 
is probably lower in families with sporadic CD patients than in our study population. The true 
prevalence of CD in our families remains unclear because 35.9% of the first-degree relatives 
refused to participate in this study. It is expected that they were less symptomatic than those 
relatives who participated.  
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6.2    Methods 
Diagnostic criteria for CD 
The strict criteria used for the diagnosis of CD in our study lead to a smaller but more 
homogenous set of affected sib-pairs, thereby increasing the chance of detecting significant 
linkage in the genome-wide scan. By these strict criteria some relatives with CD were omitted 
(slight villous atrophy with positive CD antibody tests), although they were clinically treated 
as CD patients. Altogether 90.3% of CD patients included in the genome-wide scan had total 
or subtotal villous atrophy at the time of diagnosis. After one year on GFD 84.3% had normal 
villous structure or slight villous atrophy thus confirming the diagnosis of CD and reflecting 
good adhearence to GFD by most of the CD patients. 
 
Antibody testing 
The results of the CD antibody testing showed that EMA and ARA were negative in 16.7% 
and 23.8%, respectively, of patients found to have CD in our families). AGA was more 
sensitive, but unspecific, partly because of the threshold of AGA positivity which was low in 
the laboratory we used. EMA, ARA, and AGA measurements were done in the same 
laboratory, which should have high quality of CD antibody tests. However, sensitivity and 
specificity of the serological tests have been variable also in previous studies (Hill 2005). In 
some studies, serological tests have been negative in patients with partial villous atrophy 
(Rostami et al. 2000, Abrams et al. 2004), whereas in a Finnish study EMA was negative in 
the case of advanced CD (Salmi et al. 2006b). The possibility of the IgA-defiency of our 
study subjects was ruled out by determing S-IgA level from all the study subjects. In addition, 
IgG-AGA was measured from all the study subjects. tTG antibody test was not performed 
because the method was not available at the time when our study was started. 
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Assessment of symptoms 
The lack of validated assessment of symptoms of CD makes it difficult to assess the value of 
a symptom questionnaire. In our study, the questionnaire was completed prospectively before 
the histology of biopsies was known. CD patients who had been diagnosed before our study 
had significantly more often GI symptoms than those CD patients who were diagnosed to 
have CD in the present study (data not shown). Also CD patients, who were diagnosed in our 
study, had significantly more symptoms than relatives who did not have CD. However, GI 
symptoms occurred frequently also in non-affected relatives. These findings imply that the 
use of GI symptoms as a tool to diagnose CD has a limited value.  
 
6.3    Genetics of coeliac disease (Study I) 
In our genome-wide scan two gene regions (6p and 2q23-32) had a significant association 
with CD, and one gene region (10p) had a possible association. Based on twin and family 
studies, CD had an obvious genetic background but the previously known HLA genes were 
estimated to account for less than 50% of the genetic component of CD (Petronzelli et al. 
1997, Bevan et al. 1999b). The assessment of susceptibility genes for CD is likely to clarify 
the pathogenesis of CD and give new possibilities for the diagnosis and therapy of CD. 
 
The strongest association peak was found in the HLA region on chromosome 6p. This HLA 
association could be explained by the association with the DQ2 haplotype in agreement with 
several previous studies (Table 3). 
 
The significant association with the region 2q23-32 was interesting, because in many 
candidate gene studies for CD the association with the genes CTLA-4 and/or CD 28 in this 
region has been proposed (Table 4)  and both the CTLA-4 and the CD28 genes are involved in 
 82
T cell activation and proliferation. Furthermore, the CTLA-4 gene has been associated with 
other autoimmunity diseases (Zhernakova et al. 2005). The results of the candidate gene 
studies have, however, been conflicting (Table 4). It is possible that another gene in the 
vicinity of the CTLA-4 or the CD 28 genes is responsible for the association (King et al. 
2002).  In our original study population, the association with the CTLA-4 gene was not found. 
When our results were pooled with three previous studies (Clot et al. 1999, Naluai et al. 2000, 
Mora et al. 2003), combined results indicated a significant association with the CTLA-4 gene. 
These combined results may be biased by previous negative results. Three previous negative 
studies for an association of the CTLA-4 +49*A/G with CD were not included since they did 
not report the raw data for the variant determined (+49*A/G), or had genotyped genetic 
markers nearby (Holopainen et al. 1999, King et al. 2002, Popat et al. 2002d).   
 
Our genome-wide scan identified a possible CD susceptibility locus on chromosome 10p. The 
same region showed a nominal signifigance also in a genome-wide scan in North American 
families (Neuhausen et al. 2002). Thus far, promising candidate genes for CD in this region 
have not been published. Additional markers and additional families are needed to determine 
the importance of this locus.  
 
There are several reasons for conflicting results between genome-wide scans in different 
populations (Table 3). The lack of replication of original linkage study results is a common 
problem in complex diseases, partially related to low power of studies to detect genes of 
relatively small effect and/or to a high degree of genetic heterogeneity among families (Risch 
et al. 1996, Bevan et al. 1999b, Sollid et al. 2005b). Larger data sets with more statistical 
power are needed to confirm the linkage. Single-nucleotide polymorphism -method, which 
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has not been applied in genome-wide screenings for CD, might provide new possibilities to 
identify genes predisposing for CD. 
 
6.4 Role of the HLA alleles DQA1*0501 and DQB1*0201 in coeliac disease (Studies II 
and IV)    
Our study was the first one aiming to investigate the association of the DQA1*0501 and 
DQB1*0201 alleles with different degrees of villous atrophy at the time of diagnosis of CD, 
and after one year on GFD. In a previous study on paediatric CD patients, in whom a crude 
grading of villous atrophy as “subtotal or non-subtotal” and “typical or atypical” was used, no 
association between the gene-dose effect of either the HLA DQ2 haplotype or the 
DQB1*0201 allele and CD was found (Zubillaga et al. 2002). Based on our results, it is likely 
that the carriers of the two DQB1*0201 alleles have more severe villous atrophy and are more 
resistant to GFD. In addition, refractory CD seems to be associated with the homozygosity of 
the HLA DQ2 haplotype (Al-Toma et al. 2006). 
 
Our study was the first one to investigate the contribution of the number of the DQA1*0501 
and DQB1*0201 alleles on laboratory parameters reflecting the nutritional status. At 
diagnosis, haemoglobin level was significantly lower in subjects who were homozygous for 
the DQB1*0201 allele compared to other subjects, even after the adjustment for gender and 
the degree of villous atrophy. Thus, the homozygosity for DQB1*0201 could be associated 
with villous atrophy, extending more distally in the small intestine. Moreover, also serum iron 
and folate of erythrocytes tended to be lower in subjects homozygous for the DQB1*0201 
allele. The absorption of iron and folate occurs in the proximal part of small intestine, a region 
most often and most seriously affected in CD. 
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In our study the age at diagnosis was significantly lower in carries who were homozygous for 
the DQB1*0201 allele than in patients without the DQB1*0201 alleles. In previous studies the 
results have been conflicting (Table 2). In a large Italian study, where also the frequency of 
the DQB1*0201 allele was determined, a trend towards a younger age at diagnosis was found 
in homozygous carries of the DQB1*0201 allele (Greco et al. 1998b). In contrast, in a 
Norwegian study a significant correlation of the homozygosity for the DQB1*0201 allele with 
later onset of CD was found. However, the Norwegian study included only paediatric patients 
who were arbitrarily divided into two groups of early and late onset of CD (Ploski et al. 
1993). Taken together, based on our study and a previous Italian study (Greco et al. 1998b), 
the presence of the two DQB1*0201 alleles seems to be associated with low age at diagnosis 
of CD. 
 
The assessment of the effect of the dose of the DQA1*0501 and DQB1*0201 alleles on 
symptoms of CD is unreliable because of the lack of a validated clinical assessment. 
According to our results the homozygosity of the DQB1*0201 allele was associated with 
severe abdominal pain, severe diarrhoea, and with a more frequent stools at the time of CD 
diagnosis. In previous studies, the results concerning the symptoms and the gene-dose effect 
have been controversial (Table 2). Other genes than HLA, the amount of gluten intake 
(Carlsson et al. 2006), and behavioural aspects might influence the frequency of symptoms 
reported. GI symptoms were common in non-affected relatives regardless of their HLA status 
(Study IV; Table 9).  
   
Strong association of CD with the HLA DQ2 haplotype has been previously published (Sollid 
et al. 1989, Sollid et al. 1990, Tighe et al. 1992, Congia et al. 1992, Louka et al. 2003, Karell 
et al. 2003). One of the DQA1*0501 or DQB1*0201 alleles encoding the HLA-DQ2 
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heterodimer, appears to be sufficient for conferring susceptibility to CD (Sollid et al. 1993, 
Karell et al. 2003). However, in several studies, including our study, the risk for CD has been 
significantly greater in subjects homozygous for the DQ2 haplotype or the DQB1*0201 allele 
than in subjects heterozygous for this haplotype or allele or in subjects without these alleles 
(Table 2). The HLA DQ2 molecules, which are formed by different number of DQA1*05 and 
DQB1*02 alleles, might bind with different affinity to the peptides derived from gluten and 
modified by enzymes, especially the tTG enzyme. Furthermore, the magnitude of the T-cell 
reaction, which appears to be a concequence of the peptide binding with the HLA DQ2 
molecule, is influenced by the number of the DQA1*05 and the DQB1*02 alleles (Vader et al. 
2003). These new pathogenic data also support our results of the gene-dose effects of the 
DQB1*0201 allele on the severity of CD. 
 
6.5    Screening for coeliac disease in families (Studies II, III and IV) 
Our study was the first one to confirm that the HLA genotyping could be used to exclude a 
part of the first-degree relatives (about 20%) from further CD screening (Study III). In 
offspring of CD patients, even more subjects could be excluded (over 25%). Thus, the HLA 
genotyping is particularly useful in the offspring of CD patients because they have longer life-
time expectancy than siblings of CD patients. Furthermore, the HLA genotyping is probably 
beneficial also in sporadic CD cases, because the frequency of the HLA-associated risk alleles 
is expected to be lower among first-degree relatives than in our families which were multi-
affected with CD. All HLA alleles (DQA1*0501, DQB1*0201, and DRB1*04) should be 
determined regardless of the HLA status of the index patient in a family (Study III; Table 8). 
It is possible that by genotyping the DQB1*0302 allele, which encodes the DQ8 heterodimer, 
instead of the DRB1*04 allele even more family members could have been excluded from 
further screenings.  
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Which is the best screening method for the first-degree relatives who carry the HLA-
associated risk alleles remains unclear. Because of the relatively high risk of CD in families, 
heterogeneity of the symptoms (Study IV), and the complications of untreated CD, the 
screening for CD in families has been recommended although the natural history and the 
prognosis of asymptomatic CD remain largely unknown (Collin 2005, Cranney et al. 2005, 
Hoffenberg 2005). Based on our study population (Study III and IV), the screening by EMA 
would lead to missing of almost 20% of the relatives having CD. The sensitivity and 
specificity of serological tests have been variable also in previous studies (Rostami et al. 
1999, Dickey et al. 2000, Tursi et al. 2001, Abrams et al. 2004, Salmi et al. 2006b). When 
AGA was determined in addition to EMA, the percentage of missed CD cases was lower on 
the cost of lower specificity and increased number of EGDs (Table 10). Even EGD can miss 
cases of CD if the quality of small bowel mucosal biopsies is not good, lesions of CD are 
patchy, or the pathologist is not experienced to diagnose CD (Dewar et al. 2005). In addition, 
EGD as a screening test is an invasive and also expensive procedure even in a high-risk 
group. Recently, tTG antibody test has proven to be at least as good in sensitivity and 
specificity than is EMA, and it is easier and cheaper to perform (Collin 2005, Hill 2005). In 
future, the deamidated gliadin peptide antibody test might provide a new screening method 
for CD with high sensitivity and specificity (Kaukinen et al. 2007). 
 
Because of the lifetime risk of CD the timing of CD screening is difficult. Relatives who have 
positive EMA (or ARA), but no villous atrophy on duodenal biopsies, should be screened 
further by EGD, because they are at risk to develop CD in future (Mäki et al 1991, Collin et 
al. 1993, Högberg et al. 2003, Salmi et al. 2006). The other relatives could be further screened 
with EMA (or alternatively tTG-antibodies), because of the high risk of CD in families for 
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example with 5-year intervals (Goldberg et al. 2007). Based on our results, AGA would 
increase the sensitivity of screening but generally AGA is not recommended for screening 
because of its low specificity (Collin 2005). The relatives who are homozygous for the 
DQB1*0201 allele should probably be screened more frequently (Study II). EGD should be 
performed on all relatives with clinical suspicion of CD (GI symptoms, abnormal nutritional 
laboratory parameters, atypical symptoms) regardless of the CD antibody status. EGD is the 
most sensitive and specific screening method for CD (Study IV), but as it is an invasive and 
expensive procedure it is not feasible to screen all relatives by this method.  
 
In Figure 9, an algorithm for a screening procedure of CD in the first-degree relatives is 
suggested based on our results. First, genotyping of the HLA risk alleles DQA1*0501, 
DQB1*0201, and DRB1*04 (or DQB1*0302) should be performed. All relatives carrying any 
of the HLA risk alleles should be further screened for CD with EMA (or alternatively tTG) 
and possibly AGA. IgG-antibodies should be used in case of selective IgA-deficiency. If 
antibody tests are positive or any symptoms related to CD exist, EGD should be performed. 
The antibody screening should be performed repeatedly because of the lifetime risk of CD. 
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Figure 9.  Algorithm for screening for CD in the first-degree relatives (IV). 
 ** Current guidelines recommend not to use AGA in the screening of CD. 
 
 
6.6    Concluding remarks 
In this study of 54 Finnish families with CD, a genome-wide scan was performed to identify 
susceptibility loci for CD. In addition, the genotype and phenotype correlations of CD were 
investigated, and different screening methods for CD in the first-degree relatives were tested. 
CD develops as a result of an interaction between genetic, environmental, and immunological 
factors.  
 
Three loci which associate with CD were found (6p, 2q23-32, 10p) in our genome-wide scan. 
The 2q23-32 region is of special interest, because it is associated with CD also in candidate 
First-degree relatives of patients with CD
HLA genotyping* Negative -> 
No further screening
Positive
EMA and AGA
screening
Positive or severe
symptoms
Gastroscopy
*DQA1*0501, DQB1*0201, DRB1*04
       **
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gene studies and includes genes involved in the T-cell activity. The 6p region includes the 
previously known and confirmed HLA region, whereas the 10p region does not involve any 
genes proposed for CD so far. The limitation of genome-wide scans in complex diseases is a 
low power to detect genes of minor effect (Risch et al. 1996; Bevan et al. 1999b). The results 
of genome-wide scans have varied in different populations. In the future, genome-wide scan 
using single nucleotide polymorphisms covering the entire genome should be performed. 
Knowledge on the genetic background of CD could clarify the pathogenesis of CD and give 
new strategies for diagnosing, screening, and treatment of CD. Furthermore, CD could 
provide a model for understanding other autoimmune diseases, because it is an autoimmune 
disease where the interaction between environmental factors (gluten-related proteins) and 
other parts of the pathogenesis are quite well understood. 
 
Better knowledgement of the genetic background of CD would also help us to understand 
different phenotypes of CD. In our study, the dose of the DQB1*0201 allele seems to 
contribute to the severity of CD assessed by the degree of villous atrophy, laboratory 
parameters, age, and GI symptoms at the CD diagnosis, whereas the dose of the DQA1*0501 
allele did not have such an effect. It is likely, that also environmental factors, such as amount 
of gluten intake, contribute to the clinical features of CD. 
 
Because of the heterogenity of the symptoms of CD and the life-time risk for CD in 
genetically disposed individuals, screening for CD in families is challenging. By using the 
HLA allele genotyping, a part of the relatives could be excluded from further screenings. The 
rest of the relatives should be further screened for CD. The problem of the serological 
screening is varing sensitivity and specificity of different CD antibodies, as well as the fact 
that it reflects only the status of CD at the moment the screening is done and not the risk of 
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CD in future. Resolvement of the genetics of CD might give new tools also for screening. 
Cost-effectiveness of different screening strategies in families and a possible mental burden 
caused to relatives by HLA genotyping need to be studied. 
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7. SUMMARY  
 
 
In this study of 54 Finnish families with CD, the genetic background of CD and phenotype 
differences associated with the genetic background were investigated. In addition, screening 
methods for the first-degree relatives of CD probands were investigated with a special interest 
on the HLA genotyping as an initial test. 
 
Study I: In a genome-wide scan a significant association with the chromosomal region 6p and 
2q23-32 and a suggestive association with the region 10p were found. In addition, an 
association of the CTLA-4 gene which is located within the region 2q23-32 with CD was 
observed. 
 
Study II: The gene-dose effect of the HLA DQB1*0201 allele, but not of the DQA1*0501 
allele, was found to contribute to the severity of CD assessed by the grade of villous atrophy 
at diagnosis and after one year on therapy, blood haemoglobin level, age, and GI symptoms at 
diagnosis. 
 
Study III: Genotyping for the HLA alleles DQA1*0501, DQB1*0201, and DRB1*04 was 
found to be useful in excluding about 20% of the first-degree relatives from further screening 
for CD. The benefit was greatest in the offspring of the CD probands. 
 
Study IV: GI symptoms were frequent, but mostly mild or even totally lacking, in the first-
degree relatives who were found to have CD by screening. EMA was negative in 16.7% of the 
affected relatives. AGA was more sensitive, but unspecific. An algorithm based on an initial 
HLA genotyping for the screening of CD in the first-degree relatives was suggested.   
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